Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Change in Accured Expenses (2018 - 2025)

Exagen (XGN) has disclosed Change in Accured Expenses for 8 consecutive years, with $681000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 32.37% year-over-year to $681000.0, compared with a TTM value of $251000.0 through Dec 2025, up 288.72%, and an annual FY2025 reading of $251000.0, up 288.72% over the prior year.
  • Change in Accured Expenses was $681000.0 for Q4 2025 at Exagen, down from $1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.2 million in Q3 2023 and bottomed at -$1.4 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $109850.0, with a median of $300000.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 645.45% in 2022, then surged 903.37% in 2023.
  • Year by year, Change in Accured Expenses stood at $446000.0 in 2021, then crashed by 387.22% to -$1.3 million in 2022, then skyrocketed by 138.8% to $497000.0 in 2023, then skyrocketed by 102.62% to $1.0 million in 2024, then tumbled by 32.37% to $681000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for XGN at $681000.0 in Q4 2025, $1.2 million in Q3 2025, and -$192000.0 in Q2 2025.